Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer | Zendy

Vijay Agarwal | Zendy; Rajendra Prasad | Zendy; Mohammad Butt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer

Author(s) -

Vijay Agarwal,

Rajendra Prasad,

Mohammad Butt

Publication year - 2009

Publication title -

clinical medicine therapeutics

Language(s) - English

Resource type - Journals

ISSN - 1179-1713

DOI - 10.4137/cmt.s1949

Subject(s) - bevacizumab , medicine , lung cancer , chemotherapy , oncology , angiogenesis , targeted therapy , cancer , monoclonal antibody , cancer research , pharmacology , immunology , antibody

Lung cancer is the most common cause of cancer mortality worldwide and even with current advances in chemotherapy the outcome is disappointing. The advances in molecular biology have enabled us to identify various targets for anticancer treatments. The VEGF-VEGFR signalling pathway plays a significant role in tumor angiogenesis and has been a major target for the development of various anticancer drugs. Bevacizumab is a recombinant humanized monoclonal antibody, which binds to VEGF and has shown efficacy in various tumors. Bevacizumab has been licensed in first line treatment of non-small cell lung cancer (NSCLC) in combination with chemotherapy. We are reviewing the evidence of the benefit and toxicity of Bevacizumab in combination with chemotherapy and other targeted agents in advanced NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research